Phase 2 trial of FX 322 for hearing regeneration

Trial Profile

Phase 2 trial of FX 322 for hearing regeneration

Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs FX 322 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2018 New trial record
    • 15 Feb 2018 According to a Frequency Therapeutics media release, this trial is anticipated to begin in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top